09 / 74 · 1:02 · Original AXON film
CJC-1295 + Ipamorelin
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
Two pathways | One evidence question
CJC-1295 and ipamorelin approach growth-hormone signalling through different routes. That is a mechanism story, not yet proof of a useful combination. [1] [2]
GHRH analogue • GH secretagogue
CJC-1295 is a growth-hormone-releasing-hormone analogue. Ipamorelin is a growth-hormone secretagogue. Their individual pharmacology explains why people discuss them together. [1] [2]
HUMAN DATA: hormone endpoints
Small human studies of long-acting CJC-1295 measured increases in growth hormone and IGF-one. They did not establish that adding ipamorelin improves health, strength or longevity. [1]
Exact formulation matters
FDA has raised safety concerns about these substances. Also check the exact CJC formulation: products described as with or without DAC cannot inherit one another’s evidence. [3] [4]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults →Primary randomized placebo-controlled human studies of long-acting CJC-1295
- Ipamorelin, the first selective growth hormone secretagogue →Primary preclinical pharmacology
- FDA Pharmacy Compounding Advisory Committee briefing: CJC-1295-related substances →US regulator technical assessment; distinct chemical forms and safety
- FDA: Certain bulk drug substances that may present significant safety risks →US regulator; route-specific safety assessment, not a universal ban or approval list
